Photo taken from fiercepharma.com
Jul 27, 2024, 13:56
ASCO Rapid Recommendation Update on Management of Stage III NSCLC
Estela Rodriguez shared a paper by Megan E. Daly et al. on X, adding:
“Hot Off the press:
ASCO Rapid Recommendation Update on Management of Stage III Non–Small Cell Lung Cancer:
- Strong recommendation for osimertinib consolidation post chemoRT given magnitude of PFS advantage in LAURA trial.
- Evidence: moderate pending OS results.
- Duration of therapy and AEs need to be discussed with patients.”
Source: Estela Rodriguez/X
Estela Rodriguez is Associate Director of Community Outreach and Co-Lead of Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine. She is board certified in medical oncology and hematology. She has a special interest in the early detection of lung cancer and increasing access to clinical trials.
Management of Stage III Non–Small Cell Lung Cancer: ASCO Rapid Recommendation Update.
Authors: Megan E. Daly, Navneet Singh, and Nofisat Ismaila.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12
Nov 20, 2024, 19:11